Robert Harrington to Factor Xa Inhibitors
This is a "connection" page, showing publications Robert Harrington has written about Factor Xa Inhibitors.
Connection Strength
1.789
-
Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease. Thromb Haemost. 2004 Dec; 92(6):1182-93.
Score: 0.229
-
Combined coagulation phase-directed factor Xa inhibition with heparin compounds and DX-9065a - a direct and selective antagonist. Thromb Haemost. 2004 Dec; 92(6):1229-31.
Score: 0.229
-
First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation. Circulation. 2002 May 21; 105(20):2385-91.
Score: 0.192
-
Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: Findings From the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial). Circulation. 2018 01 02; 137(1):91-94.
Score: 0.142
-
Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: Insights from the APEX Trial. Thromb Haemost. 2017 12; 117(12):2389-2395.
Score: 0.141
-
Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. J Am Heart Assoc. 2017 Jul 11; 6(7).
Score: 0.137
-
The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial. Am Heart J. 2017 Mar; 185:93-100.
Score: 0.132
-
Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. N Engl J Med. 2016 08 11; 375(6):534-44.
Score: 0.127
-
Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011 Aug 25; 365(8):699-708.
Score: 0.091
-
Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome. Thromb Haemost. 2010 Nov; 104(5):976-83.
Score: 0.085
-
Clinical consequences of bleeding among individuals with a recent acute coronary syndrome: Insights from the APPRAISE-2 trial. Am Heart J. 2019 09; 215:106-113.
Score: 0.039
-
Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy. Intensive Care Med. 2019 04; 45(4):477-487.
Score: 0.038
-
Association of Anemia with Venous Thromboembolism in Acutely Ill Hospitalized Patients: An APEX Trial Substudy. Am J Med. 2018 08; 131(8):972.e1-972.e7.
Score: 0.036
-
Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trial. Am Heart J. 2018 03; 197:1-8.
Score: 0.035
-
Competing risk analysis in a large cardiovascular clinical trial: An APEX substudy. Pharm Stat. 2017 11; 16(6):445-450.
Score: 0.035
-
Characterising and predicting bleeding in high-risk patients with an acute coronary syndrome. Heart. 2015 Sep; 101(18):1475-84.
Score: 0.030
-
Anticoagulant therapy and outcomes in patients with prior or acute heart failure and acute coronary syndromes: Insights from the APixaban for PRevention of Acute ISchemic Events 2 trial. Am Heart J. 2015 Apr; 169(4):531-8.
Score: 0.029
-
Antithrombotics in acute coronary syndromes. J Am Coll Cardiol. 2009 Sep 08; 54(11):969-84.
Score: 0.020
-
Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009 Jun 09; 119(22):2877-85.
Score: 0.020